Prostate Cancer treatment in Melbourne

Cancer is a condition in which the growth of normal cells becomes uncontrolled for reasons not entirely understood. These cells continue to divide, creating a tumour which at first grows locally within the prostate, then may spread via the lymphatics (small channels throughout the body containing lymph fluid) or bloodstream to more distant parts of the body. It can also spread microscopically into the tissues surrounding the prostate.

Prostate cancer most commonly affects the outer part of the gland, and is often slow-growing over many years. It does not usually cause any symptoms until it is locally advanced or has spread to other parts of the body. One in six Australian men is diagnosed with prostate cancer in a lifetime, and it is the second most common cause of death from cancer in men.

Australian Urology Associates provides specialist prostate cancer care across consulting locations throughout Melbourne. If you have concerns about prostate cancer or have been referred for further assessment, our team is here to help.

Prostate cancer symptoms

As prostate cancer affects the outer part of the gland most commonly (i.e. away from the urethra), it does not cause prostate cancer symptoms until it is advanced. As such it is often recommended to screen asymptomatic men to identify the disease early in its course when there is the greatest chance of cure, if treatment is required. Urinary symptoms are more often due to co-existent BPH, such as:

  • Hesitancy (difficulty starting urination)
  • Poor or intermittent urine flow
  • Feeling of the bladder not emptying completely
  • Feeling of not being able to hold on (urgency)
  • If prostate cancer spreads to other parts of the body, such as into the bones, it may cause pain in these areas.

Prostate cancer diagnosis

After taking a history for risk factors and symptoms, the prostate can be examined by passing a finger into the rectum (digital rectal examination, or DRE) and feeling the back of the prostate through the front wall of the rectum.  Any cancers large enough to cause a lump in this part of the gland will be palpable (felt). An abnormality on DRE, or a raised PSA, may raise the suspicion that prostate cancer could be present. The next step is to investigate with a MRI Prostate and if a suspicious area is identified, sample some of the prostatic tissue to examine under the microscope by doing a prostate biopsy. Alternatively, cancer may be diagnosed by chance when analyzing prostate tissue surgically removed to ‘unblock’ the flow of urine (as in transurethral resection of the prostate or TURP).

Stages of prostate cancer

These are used to determine how advanced or aggressive the prostate cancer is and therefore the likelihood of cure with treatment such as surgery or radiotherapy.

The stage refers to how far the prostate cancer is spread, and a classification system commonly used in Australia is outlined below in a simplified form (By convention, the prefix T is used to denote the tumour stage).

  • T1 the cancer is too small to be felt on rectal examination.  It has been diagnosed either through biopsy after an elevated PSA, or by chance after transurethral prostate resection.
  • T2 the cancer is large enough to form a palpable lump on rectal examination, but is still confined to the prostate gland.
  • T3 the cancer has spread outside the gland and possibly into the seminal vesicles.
  • T4 the cancer has spread to involve structures around the prostate, such as the rectum, bladder, or pelvic muscles

Grades of prostate cancer

The grade of a cancer is how aggressive the cells look under the microscope, and in prostate cancer is given a Gleason score. As prostate cancer is often multifocal, consisting of multiple spots of cancer within the prostate rather than one single tumour, separate areas of cancer can have different appearances. 

To give a Gleason score, the two appearances most commonly seen are each graded from 1 to 5 by the pathologist, giving a potential minimum total score of 2 and maximum of 10 (most aggressive). However, it has been realised that scores less than 6 can be inaccurate so that nowadays the minimum Gleason score given is 6, indicating the least aggressive-looking grade of cancer. In general, Gleason 6 cancers are non-aggressive, Gleason 7 are intermediate and Gleason 8-10 aggressive.

The grade of a cancer is how aggressive the cells look under the microscope, and in prostate cancer is given a Gleason score. As prostate cancer is often multifocal, consisting of multiple spots of cancer within the prostate rather than one single tumour, separate areas of cancer can have different appearances. 

To give a Gleason score, the two appearances most commonly seen are each graded from 1 to 5 by the pathologist, giving a potential minimum total score of 2 and maximum of 10 (most aggressive). However, it has been realised that scores less than 6 can be inaccurate so that nowadays the minimum Gleason score given is 6, indicating the least aggressive-looking grade of cancer. In general, Gleason 6 cancers are non-aggressive, Gleason 7 are intermediate and Gleason 8-10 aggressive.

Prostate cancer treatment options

There are many ways to treat prostate cancer that are still confined to the prostate (T1 or T2) and there is still no definitive agreement as to which is the best. One of the reasons for this is that patients with early stage disease may live 10 years or more if no treatment is used, whereas in others the disease can be more serious and progress quickly. While we can generalize, it is impossible to predict with certainty for any one individual the course their particular cancer may take. The first thing to note is that you should not feel pressured to make a decision. When prostate cancer is detected early, there is plenty of time to explore your options, and it is not uncommon for patients to take a few weeks or even months to decide upon which treatment they would prefer.

Active surveillance

If prostate cancer has been diagnosed very early and on biopsy is of low grade (Gleason 6 or a low Gleason 7), or incidentally during transurethral prostate resection, a ‘wait and see’ policy may be chosen to assess if the cancer is growing quickly enough to warrant treatment. The idea is to avoid unnecessary treatment, which comes with its own risks to quality of life. This does not mean doing nothing, but involves a regime of regular PSA tests, repeat imaging and prostate biopsies to monitor the cancer.  If treatment is ultimately required, it is in the form of curative treatment, such as surgery, radiotherapy or focal therapy.

This is the traditional form of prostate cancer treatment, and involves removal of the entire prostate gland along with the seminal vesicles.  The urethra is then reattached to the bladder outlet. The nerves supplying erectile function to the penis run alongside the prostate, but can often be spared, depending on various factors, giving the best chance of recovery of erectile function post-operatively. For cancer confined within the prostate, radical prostatectomy offers complete removal and subsequent analysis of the specimen for a more accurate prediction of cure. Following surgery the PSA drops to undetectable levels and is monitored closely. A rise in PSA after surgery is an indicator of very early cancer recurrence, and this may be further treated with radiotherapy in some patients.

Radical prostatectomy can be performed using open surgical or minimally invasive techniques. The open approach usually involves one longer incision below the umbilicus (belly button). The minimally invasive techniques involve laparoscopic (keyhole) surgery and can be performed with or without the help of a robot. Several very small incisions are made across the abdomen to introduce the long instruments through “ports”. Nerve-sparing can be performed via any of these techniques.

Risks of radical prostatectomy include cancer recurrence, erectile dysfunction, and urinary incontinence.

Radiotherapy is the delivery of radiation to the prostate by a specialist radiation oncologist, aiming to destroy the cancer cells, with minimal impact on surrounding normal structures (bladder, urethra and rectum).  It can also be used in a palliative setting, directed at areas of cancer outside the prostate, e.g. for relief of bone pain due to cancer spread.  Radiotherapy can be administered like an X-ray, by directing the beam from outside the body onto the prostate (external beam radiotherapy), or by inserting radioactive ‘seeds’ or needles into the prostate (brachytherapy). Following radiotherapy, the PSA slowly declines and is monitored to assess the success of prostate cancer treatment, although this can take up to 12-18 months.

Risks of radiotherapy include cancer recurrence, erectile dysfunction, urinary symptoms such as frequency, urgency and difficulty voiding, and rectal symptoms such as diarrhoea and rectal urgency. In many cases the radiation oncologist will request that we insert marker seeds into the prostate to improve the accuracy of the radiotherapy and a spacer gel between the rectum and prostate to reduce the likelihood of rectal side effects. This is done in a very similar way to the prostate biopsy.

Focal therapy treats only the area of the prostate containing significant cancer, rather than the whole gland. The aim is to control the cancer while preserving as much healthy tissue as possible, reducing the risk of side effects associated with radical treatments. It may be suitable for men whose cancer is confined to the prostate, is clearly visible on MRI, and is limited to one region of the gland.

NanoKnife, also known as irreversible electroporation (IRE), is a form of focal therapy that uses short pulses of high-voltage electricity to destroy cancer cells. The pulses create tiny holes in the walls of the cancer cells, causing them to die. Unlike treatments that use heat or freezing, NanoKnife does not damage the surrounding structural tissue, which helps protect nearby nerves, blood vessels and the urethra.

The procedure is performed under general anaesthetic. Fine needles are inserted through the skin between the scrotum and anus (the perineum), guided by ultrasound combined with MRI images, in a very similar way to a transperineal prostate biopsy. Most patients go home the same day or the following day, and a urinary catheter may be required for a few days afterwards.

Following treatment, the cancer is monitored closely with regular PSA tests, MRI and, where needed, repeat biopsy. If cancer recurs or develops elsewhere in the prostate, further focal treatment or standard treatments such as surgery or radiotherapy generally remain available.

Risks of focal therapy include cancer recurrence or untreated cancer elsewhere in the prostate, temporary urinary symptoms, urinary infection and blood in the urine. Rates of erectile dysfunction and urinary incontinence are generally lower than with radical prostatectomy or radiotherapy. As focal therapy is a newer approach, long-term outcome data is still being gathered, and it is not suitable for every patient.

This treatment is usually offered to patients in whom the cancer has spread beyond the prostate, e.g. to lymph nodes or bone.  Prostate cancer is partly driven by the male hormone, testosterone, which is made by the testicles.  By stopping the production of testosterone, the cancer usually significantly shrinks in size throughout the body, and is held dormant for a period of time that may last many years.  Ways to achieve this consist of either:

  • Surgically removing the testicles (orchidectomy)
  • Taking medications, or 3-6 monthly injections to ‘turn off’ the testicles

The effectiveness of treatment can be monitored by the PSA reading, which quickly drops in most patients.  Side effects are those of a loss of the male hormone and are similar to the menopause experienced by women as they lose their female hormones.  These may consist of fatigue, loss of libido, loss of erections, hot flushes, tender or enlarged breast tissue, loss of muscle bulk.  Over time the bones may lose strength (osteoporosis) with increased risk of fracture, and therefore it is recommended to have regular bone density scans. It can cause emotional changes like depression and in some cases may cause cognitive decline. Hormonal therapy is not a cure, as with time the cancer begins to grow again despite the treatment, but is an effective control that in some patients can last for a long period of time.

PSA testing and prostate cancer screening

The PSA (Prostate Specific Antigen) test is a blood test used as part of prostate cancer screening. It measures the level of PSA in the blood, which is produced in larger amounts when prostate cells become cancerous. The PSA test is not a perfect indicator of prostate cancer, and only around a third of men with an elevated PSA go on to receive a confirmed diagnosis.

Prostate cancer screening is generally recommended for men aged 50 and over, or from age 40 for those with a family history of the disease. If you are unsure whether prostate cancer screening is appropriate for you, our Melbourne urologists can help you weigh up the risks and benefits.

Frequently Asked Questions about Prostate Cancer

What is the prostate?

The prostate gland is a small, solid gland roughly the size of a walnut, located behind the pubic bone. It is situated beneath the bladder, surrounding the first part of the urethra. Approximately 0.5ml of each ejaculate is fluid made by the prostate, containing a number of substances that nourish the sperm and are necessary for fertility. Two small pouches, the seminal vesicles, sit directly behind the prostate, and provide a further 2ml of ejaculatory fluid via small tubes that run through the prostate into the urethra.

One of the substances secreted into the ejaculate by the prostate, Prostate Specific Antigen (PSA), is made in larger amounts when prostate cells become cancerous, and can be measured in the blood. This is therefore used as a screening test for prostate cancer. It is not a perfect test, however, and only around a third of men with an elevated PSA go on to have a diagnosis of prostate cancer made. Causes of an increased PSA test result other than cancer include:

  • BPH
  • Urine infection
  • Prostatitis
  • Urethral catheter

Professor Mark Frydenberg AM discusses the PSA blood test used to detect prostate cancer.

Prostatitis may or may not be due to infection. Severity of symptoms ranges from none to severe frequency of urination, burning pain during urination, difficulty voiding, and even complete inability to void (acute retention). If the prostate is infected, it can be a source of recurring urine infections, particularly in the setting of co-existent BPH and urinary obstruction.

The exact reason for prostate cells turning cancerous is not understood.  A number of factors have been determined to identify those at higher risk of prostate cancer, and these include:

  • Family history: Those with a first degree relative (brother or father) are around 2-3 times higher risk than normal, and this increases if more than one relative is affected
  • Age: the risk of prostate cancer increases with age, less common in men under 50
  • Genetics: Prostate cancer is more common in Africans and rarer in Asians
  • Dietary factors: There appears to be a link between prostate cancer and men consuming large amounts of dietary fat.

On top of the shock of being diagnosed with cancer, the array of possible treatment plans can leave patients feeling very confused as to which is most appropriate for them. Some patients feel surprised at being offered a choice of treatments and naturally feel inadequately prepared to make such an important decision. It may be worthwhile seeking additional consultations to discuss options, as well as second opinions from other specialists, before coming to a decision.

Read more about prostate cancer diagnosis and treatments:

Transperineal Prostate Biopsy »
Robotic Prostatectomy + Other Robotic Surgery »
Brachytherapy »
NanoKnife – Focal Irreversible Electroporation (IRE) »

Australian Urology Associates is a specialist urology practice with consulting locations across Melbourne. Our urologists have extensive experience in prostate cancer diagnosis, prostate cancer screening, and all prostate cancer treatment options, from active surveillance through to radical prostatectomy and radiotherapy.

If you have been referred to a prostate cancer specialist in Melbourne, or would like to discuss your concerns with one of our team, contact us to arrange a consultation.

Questions? Our team are here to help.